Systemic treatments (except interferon and photophoresis);Traitements systémiques des lymphomes cutanés T épidermotropes (hors interféron et photophérèse)

Annales de Dermatologie et de Venereologie

Volumn 132, Issue SPEC. ISS. 2, 2005, Pages

  Dereure, O ^a  

^a HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ALPHA INTERFERON; BLEOMYCIN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; ETRETIN; ETRETINATE; FLUDARABINE; GEMCITABINE; ISOTRETINOIN; METHOTREXATE; PENTOSTATIN; PREDNISONE; RETINOID; RETINOID X RECEPTOR; VINCRISTINE;

BLOOD TOXICITY; CUTANEOUS T CELL LYMPHOMA; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; MYCOSIS FUNGOIDES; PUVA; QUANTITATIVE DIAGNOSIS; REVIEW; SEZARY SYNDROME; SYSTEMIC THERAPY;

HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; RETINOIDS; SKIN NEOPLASMS;

EID: 25144517331     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
2. Stadler R, Otte HG, Luger T, Henz BM, Kuhl P, Zwingers T, Sterry W. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92:3578-81.
3. Dréno B, Claudy A, Meynadier J, Verret JL, Souteyrand P, Ortonne JP, et al. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate. Br J Dermatol 1991;125:456-9.
4. Dréno B, Celerier P, Litoux P. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993;89:28-32.
5. Zachariae H, Thestrup-Pedersen K. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:206S-208S.
6. Aviles A, Guzman R, Garcia EL, Diaz-Maqueo JC. Biological modifiers (etretinate and alfa 2a interferon) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biother Radiopharm 1996;11:21-4.
7. Therstrup-Pedersen K, Hammer R, Kaltoft K, Sogaard H, Zachariae H. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 1988;118:811-8.
8. Thomsen K, Hammar H, Molin L, Volden G. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989;69:536-8.
9. Zachariae H, Thestrup-Pedersen K. Combination chemotherapy with bleomycin, cyclophosphamide, prednisone and etretinate (BCPE) in advanced mycosis fungoides: a six-year experience. Acta Derm Venereol 1987;67:433-7.
10. Jones G, McLean J, Rosenthal D, Roberts J, Sauder DN. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol 1992;26:960-7.
11. Lim HW, Harris HR. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis. Dermatol Surg 1995;21:597-9.
12. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med 1987;147:529-31.
13. Kessler JF, Jones SE, Levine N, Lynch PJ, Booth AR, Meyskens FL Jr. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123:201-4.
14. Thomsen K, Molin L, Volden G, Lange Wantzin G, Hellbe L. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1984;64:563-6.
15. Molin L, Thomsen K, Volden G, Aronsson A, Hammar H, Hellbe L, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67:232-6.
16. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991;24:247-52.
17. Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SI, Cabanillas FF, Kurzrock R. Combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;34:1022-9.
18. Duvic M, Apisarnthanarax N, Cohen Ds, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003;49:35-49.
19. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
20. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84
21. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC; Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
22. Querfeld C, Rosen ST, Guitart J, Rademaker A, Fung BB, Posten W, Kuzel TM. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol 2004;51:25-32.
23. McGinnis KS, Junkins-Hopkins JM, Crawford G, Shapiro M, Rook AH, Vittorio CC. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004;50:375-9.
24. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003;139:771-5.
25. Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol 2002;1:134-6.
26. Quaglino P, Fierro MT, Rossotto GL, Savoia P, Bernengo MG. Treatment of advanced mycosis fungoides/Sézary syndrome with fludarabine and potential adjunctive benefit so subsequent extracorporeal photochemotherapy. Br J Dermatol 2004;150:327-36.
27. Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994;12:2051-9.
28. Scarisbrick JJ, Child FJ, Clift A, Sabroe R, Whittaker SJ, Spittle M, Russell-Jones R. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001;144:1010-5.
29. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. J Am Acad Dermatol 1996;34:626-31.
30. Zackheim HS, Kashani-Sabet M, Mc Millan A Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 2003;49:873-8.
31. Zackheim HS, Epstein EH Jr. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 1989;21:757-62.
32. McDonald CJ, Bertino JR. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep 1978;62:1009-14.
33. Schappell DL, Alper JC, McDonald CJ. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. Arch Dermatol 1995;131:307-13.
34. Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sézary syndrome. J Am Acad Dermatol 1984;10:1000-4.
35. Coors EA, Von Den Driesch P. Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br J Dermatol 2000;143:127-31.
36. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugnon G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-6.
37. Kong LR, Samuelson E, Rosen ST, Roenigk HH Jr, Tallman MS, et al. 2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders. Leuk Lymphoma 1997;26:89-97.
38. Bouwhuis SA, El-Azhary RA, McEvoy MT, Gibson LE, Habermann TM, Witzig TE, Pitteldow MR. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine. Int J Dermatol 2002;41:352-6.
39. Zaucha JM, Lewandowski K, Hellmann A, Pawlik H, Siedlewicz A. 2-Chlorodeoxyadenosine treatment in the Sézary syndrome. Blood 1997;89:1462-4.
40. Kuzel Tm, Hurria A, Samuelson E, Tallman MS, Roenigk HH Jr, Rademaker AW, Rosen ST. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996;87:906-11.
41. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2- Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992;80:587-92.
42. Wollina U, Graefe T, Karte K. Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 2000;42:40-6.
43. Wollina U, Graefe T, Kaatz M. Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on ten patients with follow-up. J Cancer Res Clin Oncol 2001;127:128-34.
44. Wollina U, Dummer R, Brockmeyer NH, Konrad H, Busch JO, Kaatz M, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:993-1001.
45. Levy JA, Diggs CH, Wiernik PH. Adriamycin therapy in advanced mycosis fungoides. Cancer Treat Rep 1979;63:647-53.
46. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology 2000;14:37-40.
47. Foss FM. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. Semin Oncol 2000;27:58-63.
48. Ho AD, Suciu S, Stryckmans P, De Cataldo F, Willemze R, Thaler J, et al. Pentostatin in T-cell malignancies - a phase II trial of the EORTC. Leukemia Cooperative Group. Ann Oncol 1999;10:1493-8.
49. Greiner D, Olsen EA, Petroni G. Pentostatin (2′-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36:950-5.
50. Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 1991;9:565-71.
51. Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004;100:342-9.
52. Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann AB, Schlechter GP, et al. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1992;10:1907-13.
53. Argiris A, Heald P, Kuzel T, Foss FM, DiStasio S, Cooper DL, et al. Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma. Invest New Drugs 2001;19:321-6.
54. Rijlaarsdam JU, Huijgens PC, Beljaards RC, Bakels V, Willemze R. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 1992;127:524-8.
55. Molin L, Thomsen K, Volden G, Bergqvist-Karlsson A, Hallberg O, Hellbe L. Epipodophyllotoxin (VP-16-213) in mycosis fungoides: a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol 1979;59:84-7.
56. Van Vloten WA, Polano MK. Bleomycin therapy in mycosis fungoides. Dermatologica 1975;150:50-7.
57. Akpek G, Koh HK, Bogen S, O'Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer 1999;86:1368-76.
58. Case DC Jr. Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone. Am J Clin Oncol 1984;7:453-5.
59. Fierro MT, Doveil GC, Quaglino P, Savoia P, Verrone A, Bernengo MG. Combination of etoposide, idarubicin, cyclophosphamide, vincristine, prednisone and bleomycin (BICOP-B) in the treatment of advanced cutaneous T-cell lymphoma. Dermatology 1997;194:268-72.
60. Fierro MT, Quaglino P, Savoia P, Verrone A, Bernengo MG. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998;31:583-8.
61. Molin L, Thomsen K, Volden G, Groth O, Hellbe L, Holst R, et al. Combination chemotherapy in the tumour stage of mycosis fungoides with cyclophosphamide, vincristin, vp-16, adriamycin and prednisolone (cop, chop, cavop): a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol 1980;60:542-4.
62. Molin L, Thomsen K, Volden G, Jensen P, Knudsen E, Nyfors A, Schmidt H. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report fromp the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67:179-82.
63. Sentis HJ, Willemze R, Van Vloten WA. Systemic polychemotherapy in patients with mycosis fungoides and lymph node involvement: a follow-up study of 17 patients. Acta Derm Venereol 1985;65:179-83.
64. Wilson LD, Licata AL, Braverman IM, Edelson RL, Heald PW, Feldman Am, Kacinski BM. Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy. Int J Radiat Oncol Biol Phys 1995;32:987-95.
65. Zeitoun C, Baccard M, Marolleau JP, Rybojad M, Baruchel A, Morel P, Brice P. Autogreffe de moelle osseuse dans le traitement des lymphomes cutanés. Ann Dermatol Venereol 1996;123:79-84.
66. Bigler RD, Crilley P, Micaily B, Brady LW, Topolsky D, Bulova S, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant 1991;7:133-7.
67. Ferra C, Servitje O, Petriz L, Estrach T, Marti R, Limon A, et al. Autologous haematopoietic progenitor transplantation in advanced mycosis fungoides. Br J Dermatol 1999;140:1188-9.
68. Russell-Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J. Autologous peripheral blood stem cell transplantation in tumor-stage mycosis fungoides: predictors of disease-free survival. Ann N Y Acad Sci 2001;941:147-54.
69. Ingen-Housz-Oro S, Bachelez H, Verola O, Lebbe C, Marolleau JP, Hennequin C, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transplant 2004;33:629-34.
70. Fijnheer R, Sanders CJ, Canninga MR, De Weger RA, Verdonck LF. Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2003;32:345-7.